Pharma Research Bio said Monday that it has received approval from the Ministry of Food and Drug Safety to conduct phase 1 clinical trial about BCD200, its botulinum toxin (BTX) product.

The company plans to evaluate the safety of the drug on patients with moderate to severe forehead wrinkles, and compare it with the control group.

The company aims to launch the product in Korea in 2021 while applying for a license to export the product to enter the global BTX market.

“The global BTX market is growing both in the beauty and treatment sectors, and we are discussing with our global partners for a strategy to accelerate the advance into the global market,” a company official said.